NCT04735562|CompletedDMC
Thrombospondin-4 Levels and Peripheral Arterial Disease in Hemodialysis Patients
Association of Plasma Thrombospondin-4 Levels and Peripheral Arterial Disease in Hemodialysis Patients
Loading search results
Association of Plasma Thrombospondin-4 Levels and Peripheral Arterial Disease in Hemodialysis Patients
Sponsor study identifier
observational
280
1 country
1
Study Start
April 1, 2021
Actual (reported)Primary Completion
December 31, 2021
Actual (reported)Study Completion
December 31, 2021
Actual (reported)Background: Peripheral arterial disease (PAD) a condition characterized by atherosclerotic occlusive disease of the lower extremities is commonly observed in patients with chronic kidney disease (CKD) patients, particularly those on dialysis. The investigators conducted detailed biomarkers such as thrombospondin and related inflammatory biomarkers for the risk of developing and presence of PAD. Thrombospondin-4 (TSP-4) is an extracellular matrix protein of the vessel wall. Despite bench evidence, its significance in the clinical setting of chronic kidney disease (CKD) is missing Methods: This is a cross-sectional, single-center study. A cohort of 450 patients aged 20 or over, who have been on HD for at least 3 months prior to enrollment (Dec 1, 2021) will be included. TSP-4 and TSP-1 will be measured in HD patients using a commercially available ELISA. PAD is diagnosed by the ankle-brachial index (ABI) We will measure related blood biomarkers such as serum hs-cTnT, N-terminal probrain natriuretic peptide, s-Klotho and FABP-4.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2021
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 29, 2021
Actual (reported)February 3, 2021
Actual (reported)April 1, 2021
Actual (reported)December 31, 2021
Actual (reported)December 31, 2021
Actual (reported)Analysis of biomarkers of thrombospondin-4 levels
Plasma level of thrombospondin-4 is a biomarkers for the risk of developing and presence of PAD
1 years
Ankle Brachial Index Measurements
1 years
Analysis of biomarkers of hs-cTnT
1 years
Analysis of biomarkers of N-terminal probrain natriuretic peptide
1 years
Analysis of biomarkers of a-Klotho
1 years
Analysis of biomarkers of FABP-4
1 years
patients have to be at least 20-years-old and hemodialysis (HD) for at least 3 months.
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan
Paik Seong Lim, PhD
Tungs' Taichung Metroharbour Hospital
280 participants (actual enrollment reported by the registry).
First Submitted
January 29, 2021
First Posted
February 3, 2021
Study Start
April 1, 2021
Actual (reported)Clinical Testing Study in Peripheral Arterial Disease
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2021
Actual (reported)Study Completion
December 31, 2021
Actual (reported)Last Updated
February 18, 2022
Record last verified: 2022-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: